David J. Grainger - 31 Dec 2023 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role: Chief Innovation Officer
Signature: /s/ Gregory Weinhoff, attorney-in-fact
Issuer symbol: CNTA
Transactions as of: 31 Dec 2023
Net transactions value: -$37,412
Form type: 4
Filing time: 02 Jan 2024, 19:41:07 UTC
Previous filing: 03 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNTA	Ordinary Shares	Tax liability	$37,412	-4,700	-0.49%	$7.96	962,790	31 Dec 2023	Direct	F1, F2
holding	CNTA	Ordinary Shares						27,500	31 Dec 2023	See footnote	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

David J. Grainger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
F3	Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.